BIOCRYST PHARMACEUTICALS INC (BCRX) 10.55 -0.19 (-1.77%)
10.55 -0.19 (-1.77%)
US09058V1035 - Common Stock - After market: 10.55 0 (0%)
Buy % Consensus
Analysts have set a mean price target of 16.09. This target is 52.54% above the current price.
BCRX was analyzed by 18 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about BCRX.
In the previous month the buy percentage consensus was at a similar level.
BCRX was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target
Up and Down Grades
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-11-02 | RBC Capital | Maintains | Sector Perform |
| 2022-11-02 | Evercore ISI Group | Upgrade | In-Line -> Outperform |
| 2022-08-08 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-08-05 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-08-05 | Barclays | Maintains | Equal-Weight |
| 2022-08-05 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2022-04-18 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2022-04-12 | RBC Capital | Maintains | Sector Perform |
| 2022-04-11 | Oppenheimer | Maintains | Outperform |
| 2022-04-11 | B of A Securities | Downgrade | Buy -> Neutral |
| 2021-12-10 | Oppenheimer | Initiate | Outperform |
| 2021-11-04 | RBC Capital | Maintains | Sector Perform |
| 2021-11-04 | Barclays | Maintains | Overweight |
| 2021-08-06 | JMP Securities | Maintains | Market Outperform |
| 2021-08-06 | RBC Capital | Maintains | Sector Perform |
| 2021-08-06 | Barclays | Maintains | Overweight |
| 2021-08-06 | Jefferies | Downgrade | Buy -> Hold |
| 2021-08-06 | HC Wainwright & Co. | Maintains | Buy |
| 2021-08-03 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-03-24 | HC Wainwright & Co. | Maintains | Buy |
Analyst Ratings Stock Screener Links
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA